XL114

News alerts, weekly reports and conference planners

Company:

Dr. Reddy’s

Drug class:

CARD11-BCL10-MALT1 signaling pathway inhibitor, FABP5 inhibitor

‹

›

1year

A Study of AUR104 in Patients with Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (clinicaltrials.gov)

P1, N=42, Recruiting, Aurigene Discovery Technologies Limited

1 year ago

New P1 trial

AU7R-104 • XL114

over2years

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P1, N=2, Terminated, Exelixis | N=144 --> 2 | Trial completion date: Dec 2025 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Nov 2022; Due to Sponsor reasons.

over 2 years ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

XL114

3years

A First-in-Human Phase 1 Dose Escalation and Expansion Study of the Oral CARD11-BCL10-MALT1 Signaling Pathway Inhibitor XL114 in Patients with Non-Hodgkin's Lymphoma (ASH 2022)

Exploratory endpoints include the relationship between pharmacokinetics, pharmacodynamics, tumor and blood biomarkers, efficacy, and safety. The study has started screening patients, with total enrollment estimated to be up to 144 patients.

3 years ago

Clinical • P1 data

CARD11 (Caspase Recruitment Domain Family Member 11) • MALT1 (MALT1 Paracaspase)

XL114